CVS Lines Up Sandoz’s Adalimumab Biosimilar For US Biosimilars Subsidiary

Hyrimoz 100mg/ml To Launch Q1 2024; Business Will ‘Expand Supply Chain’

CVS feels its newly launched, wholly owned US biosimilars subsidiary called Cordavis is a “logical evolution for us and will help ensure sufficient supply of biosimilars in the US and support this market now and in the future.”

CVS signage on building
• Source: Shutterstock

The US pharmacy giant CVS Health is to contract with global biosimilars player Sandoz to commercialize and bring to market its Hyrimoz (adalimumab-adaz) biosimilar to Humira as the first product imagined by the launch of its wholly owned US biosimilars subsidiary called Cordavis.

According to CVS, the Cordavis products “will be US Food and Drug Administration approved, high quality, and easy for patients to use and will help ensure

More from Biosimilars

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By 

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By 

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By 

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By 

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

More from Products